Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from SELLAS Life Sciences Group ( (SLS) ) is now available.
On January 23, 2025, SELLAS Life Sciences Group announced positive interim results from its Phase 3 REGAL trial evaluating galinpepimut-S (GPS) for acute myeloid leukemia (AML). The Independent Data Monitoring Committee (IDMC) recommended the trial continue without modifications, citing GPS’s safety and efficacy in surpassing futility criteria and showing a promising median survival rate for patients. With fewer than 50% of patients deceased after a median follow-up of 13.5 months, these results indicate a potential shift in standard care for AML, pending further data upon reaching 80 events. The company is preparing for regulatory submissions, indicating potential transformative impacts on treatment options available for AML patients.
More about SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for a broad range of cancer indications. Its lead product candidate, galinpepimut-S (GPS), targets the WT1 protein present in various tumor types, and the company is also developing SLS009, a CDK9 inhibitor with high potential in treating AML.
YTD Price Performance: 7.48%
Average Trading Volume: 1,288,148
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $80.94M
See more data about SLS stock on TipRanks’ Stock Analysis page.
